Condition

HIV-1

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 65 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials65
Recruiting3
Common interventions25
Lead sponsors shown15
Advertisement

Clinical trials

60 shown
Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE Study)NCT07481175 · 2026-04-13
RECRUITING
Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)NCT06967753 · 2025-07-31
RECRUITING
CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDSNCT06252402 · 2024-12-19
RECRUITING
DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kgNCT07862569 · 2026-12-23
NOT_YET_RECRUITING
bNAbs and Anti-PD-1 in HIVNCT07820813 · 2026-09-15
NOT_YET_RECRUITING
Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral TherapyNCT06680479 · 2025-04-01
SUSPENDED
A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral TherapyNCT05612178 · 2023-07-26
ACTIVE_NOT_RECRUITING
MK-8510 Monotherapy for the Treatment of Anti-retroviral naïve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8510-002)NCT05700734 · 2023-04-17
WITHDRAWN
A Study of CL-197 Capsules in Healthy ParticipantsNCT05944848 · 2022-11-16
COMPLETED
Third-Generation CAR-T-cell Therapy in Individuals With HIV-1 InfectionNCT04863066 · 2021-05-01
UNKNOWN
A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight GainNCT04442737 · 2020-07-01
COMPLETED
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1NCT04223804 · 2020-01-30
COMPLETED
Preventing Childhood HIV: Rescue Intervention. ANRS 12388 PREVENIR-PEVNCT03869944 · 2019-12-04
UNKNOWN
Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo TabletsNCT04006704 · 2019-10-10
COMPLETED
A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan AfricaNCT03060629 · 2017-11-03
TERMINATED
A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of CareNCT03227861 · 2017-07-31
COMPLETED
Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic AdultsNCT02840474 · 2017-04-24
COMPLETED
Evaluation of a Short Version Computerized Test for Processing Speed to Detect Cognitive Disorders in HIV+ PatientsNCT03279835 · 2017-03-16
COMPLETED
Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With AtriplaNCT02547844 · 2015-09-01
COMPLETED
HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based RegimenNCT02513147 · 2015-06-01
COMPLETED
Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing RegimenNCT02285114 · 2015-01-20
COMPLETED
Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)NCT02275780 · 2014-12-01
COMPLETED
Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive AdultsNCT01968551 · 2013-09-03
COMPLETED
Nutritional and Metabolic Disorders in HIV Infected Children and AdolescentNCT01771562 · 2013-04-01
COMPLETED
Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1NCT01345630 · 2011-09-01
TERMINATED
PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA TrialNCT01192035 · 2011-05-01
COMPLETED
A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 YearsNCT00799864 · 2011-01-01
COMPLETED
TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected ParticipantsNCT00980538 · 2009-12-09
COMPLETED
Safety and Immunogenicity of MVA.HIVconsv in HIV-1 Seropositive Adults on HAARTNCT01024842 · 2009-12-01
TERMINATED
Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1-infected MothersNCT00981695 · 2009-11-01
UNKNOWN
Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1/2-uninfected MothersNCT00982579 · 2009-11-01
COMPLETED
Intrauterine Insemination In HIV-Discordant CouplesNCT01173276 · 2009-09-01
TERMINATED
Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1NCT00807443 · 2009-09-01
COMPLETED
Genotypic Resistant HIV Strains in TaiwanNCT00954863 · 2009-08-01
UNKNOWN
Non-Interventional Study Of Celsentri® In Treatment Experienced Patients With CCR5-Tropic HIV-InfectionNCT00850395 · 2009-07-01
COMPLETED
A Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1NCT00824369 · 2009-07-01
TERMINATED
A Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 ReplicationNCT00840762 · 2009-03-01
UNKNOWN
A Study Of Different Doses Of UK-453, 061 Plus Truvada Compared To Efavirenz Plus Truvada In Patients Who Have Not Been Previously Treated For HIV-1NCT00824421 · 2009-02-01
COMPLETED
Treatment De-Intensification and Residual HIV-1 in YouthNCT00867854 · 2009-02-01
COMPLETED
PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral DarunavirNCT00838760 · 2009-02-01
COMPLETED
TMC278-TiDP38-C145: A Bioavailability Study in Healthy Adult Volunteers to Evaluate 3 Pediatric Formulations of TMC278 (a Solution, a Suspension, and Granules) Compared to an Adult Tablet FormulationNCT00812292 · 2009-01-01
COMPLETED
TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and AdolescentsNCT00665847 · 2008-11-01
COMPLETED
TMC278-TiDP15-C150: Trial to Examine Safety, Tolerability and Plasma Pharmacokinetics of Multiple Doses of TMC278LA.NCT00741741 · 2008-07-01
TERMINATED
TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase InhibitorsNCT00543725 · 2008-06-01
COMPLETED
TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.NCT00540449 · 2008-05-01
COMPLETED
Phase 1 Safety Study of Two Experimental HIV VaccinesNCT00479999 · 2007-05-24
COMPLETED
Dermal HIV-1 Immunization During Anti-retroviral Therapy Followed by Repeated Treatment InterruptionsNCT01140139 · 2006-09-01
COMPLETED
A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and AdolescentsNCT00355524 · 2006-06-01
COMPLETED
Follow up of Thai Adult Volunteers With Breakthrough HIV Infection After Participation in a Preventive HIV Vaccine TrialNCT00337181 · 2006-05-01
COMPLETED
Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.NCT00298350 · 2006-02-01
COMPLETED
A Study in Asymptomatic HIV Infected Patients to Investigate Pharmacodynamics, Pharmacokinetics, Safety and Toleration of UK-453,061NCT00348673 · 2006-02-01
COMPLETED
Fuzeon Viral Decay Pilot StudyNCT00334022 · 2006-02-01
COMPLETED
A Safety Study of Dapivirine (TMC120) Vaginal Microbicide Gel in BelgiumNCT00309205 · 2005-12-01
COMPLETED
A Comparison Study of Kaletra Soft-Gel Capsules and Kaletra Tablets in an African American CohortNCT00268827 · 2005-12-01
COMPLETED
HLA-B35 Alleles and AIDSNCT00340223 · 2005-09-01
WITHDRAWN
Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV SubjectsNCT00144833 · 2005-03-01
TERMINATED
Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have Received OZ1 Gene Therapy as Part of a Clinical TrialNCT01177059 · 2004-12-06
COMPLETED
Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/LamivudineNCT00098293 · 2004-11-01
COMPLETED
Retrovirus Epidemiology Donor Study-II (REDS-II)NCT00097006 · 2004-09-01
COMPLETED
A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018)NCT00849732 · 2003-06-01
COMPLETED

Common interventions

TMC278DRUG4efavirenzDRUG2maravirocDRUG2MVA.HIVABIOLOGICAL2PlaceboOTHER2RitonavirDRUG21 mg CL-197 capsulesDRUG110 mg CL-197 capsules or CL-197 placeboDRUG110-1074-LSBIOLOGICAL110-1074-LSDRUG1100 mg CL-197 capsules or CL-197 placeboDRUG12 NRTIDRUG130 mg CL-197 capsules or CL-197 placeboDRUG13BNC117-LSDRUG13BNC117-LSBIOLOGICAL13M-052-AFBIOLOGICAL13rd ARV agentDRUG160 mg CL-197 capsules or CL-197 placeboDRUG1AbacavirDRUG1ABBV-181DRUG1Ad26.Mos4.HIVBIOLOGICAL1Aluminum Hydroxide SuspensionBIOLOGICAL1Baseline DRV- containing ARV regimenDRUG1Blood drawOTHER1Boosted PIsDRUG1

Trial status mix

COMPLETED44
TERMINATED7
UNKNOWN5
RECRUITING3
NOT_YET_RECRUITING2
WITHDRAWN2
ACTIVE_NOT_RECRUITING1
SUSPENDED1

Phase mix

PHASE120
PHASE218
PHASE310
PHASE47
NA2
EARLY_PHASE11
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.